Rep. Dwight Evans Sells CVS Health Corporation (NYSE:CVS) Shares

Representative Dwight Evans (D-Pennsylvania) recently sold shares of CVS Health Corporation (NYSE:CVS). In a filing disclosed on December 19th, the Representative disclosed that they had sold between $1,001 and $15,000 in CVS Health stock on November 21st. The trade occurred in the Representative’s “PERSHING LLC” account.

Representative Dwight Evans also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 11/21/2025.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of American Water Works (NYSE:AWK) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of Apollo Global Management (NYSE:APO) on 11/21/2025.
• Sold $0 – $1,000 in shares of Kyndryl (NYSE:KD) on 10/10/2025.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 10/10/2025.

CVS Health Trading Up 0.8%

CVS Health stock opened at $78.37 on Tuesday. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. The stock has a market cap of $99.49 billion, a P/E ratio of 206.24, a PEG ratio of 0.77 and a beta of 0.48. The firm’s 50 day moving average price is $79.09 and its 200-day moving average price is $72.60. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $85.15.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The firm had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. During the same period in the prior year, the company earned $1.09 EPS. The business’s revenue was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, equities analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CVS Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Aptus Capital Advisors LLC lifted its stake in shares of CVS Health by 3.4% in the 1st quarter. Aptus Capital Advisors LLC now owns 12,422 shares of the pharmacy operator’s stock valued at $842,000 after purchasing an additional 412 shares during the last quarter. Wellington Management Group LLP boosted its stake in CVS Health by 83.2% during the first quarter. Wellington Management Group LLP now owns 403,365 shares of the pharmacy operator’s stock worth $27,328,000 after buying an additional 183,232 shares during the period. Legacy Financial Advisors Inc. acquired a new stake in shares of CVS Health during the first quarter valued at about $260,000. Dorsey & Whitney Trust CO LLC raised its stake in shares of CVS Health by 10.7% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 7,378 shares of the pharmacy operator’s stock valued at $500,000 after acquiring an additional 715 shares during the period. Finally, Candriam S.C.A. lifted its holdings in shares of CVS Health by 112.4% in the 1st quarter. Candriam S.C.A. now owns 234,091 shares of the pharmacy operator’s stock worth $15,860,000 after acquiring an additional 123,891 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on CVS. UBS Group restated an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research report on Monday, December 15th. Wells Fargo & Company cut their price objective on shares of CVS Health from $103.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 13th. Evercore ISI boosted their price objective on shares of CVS Health from $85.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Finally, The Goldman Sachs Group increased their target price on CVS Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $94.67.

About Representative Evans

Dwight Evans (Democratic Party) is a member of the U.S. House, representing Pennsylvania’s 3rd Congressional District. He assumed office on January 3, 2019. His current term ends on January 3, 2027.

Evans (Democratic Party) is running for re-election to the U.S. House to represent Pennsylvania’s 3rd Congressional District. He declared candidacy for the 2026 election.

Evans earned his A.A. from the Community College of Philadelphia in 1973 and his bachelor’s degree from La Salle College in 1975. He then attended Graduate Work at Temple University from 1975 to 1976. His professional experience includes working as an employment counselor/job developer for the Urban League of Philadelphia and as a teacher in the Philadelphia Public School System.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.